CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

A recent study in the journal PNAS from the lab of Julie Overbaugh reveals a previously unknown antiviral function of a gene ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Ark sold shares of Iridium Communications ( IRDM) worth over $14 million with transactions across ARKK, ARKQ and ARKX, ...

Cathie Wood, chief of Ark Investment Management, is making moves in megacap tech stocks. Last month, Wood added to her ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...